Exclusive special offer and discount title banner vector image

NORTH AMERICA OPHTHALMIC DRUGS MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

North America Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/inflammation/allergies, Retinal Disorder, Other Indications) Market by Type (Prescription Drugs, Over-the-counter Drugs) Market by Dosage Form (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments) Market by Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, Anti-allergy, Other Therapeutic Classes) Market by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Other Distribution Channels) by Geography


MARKET OVERVIEW

The North America ophthalmic drugs market is predicted to project a CAGR of 5.56% during the forecast period, 2023-2032, and is estimated to reach a revenue of $24814.37 million by 2032.

The ophthalmic drugs market growth in North America is accredited to the growing prevalence of eye conditions like macular degeneration, glaucoma, and cataracts. Whereas the rising focus on R&D is expanding the portfolio of available drugs in the market, supplemented by significant investments by ophthalmic drug manufacturers. 

While the limited access to treatment due to the high costs of ophthalmic drugs is a major growth restraint of the North America ophthalmic drugs market.

North America Ophthalmic Drugs Market

To Know More About This Report, Request a Free Sample Copy

The North America ophthalmic drugs market growth evaluation includes the analysis of the United States and Canada. The ophthalmic drugs market is steadily expanding in the United States, propelled by various factors. The increasing incidence of eye diseases, particularly among the aging population, is fueling the demand for ophthalmic drugs. Conditions like age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and dry eye syndrome are on the rise, creating a substantial need for effective treatment solutions. Progress in drug delivery technologies, including sustained-release implants and novel formulations, has enhanced the effectiveness and convenience of ophthalmic drugs, thereby contributing to market growth. Furthermore, a heightened emphasis on research and development has resulted in the introduction of innovative therapies, broadening the spectrum of available treatment choices for eye diseases.

The North America ophthalmic drugs market segmentation includes dosage form, therapeutic class, type, indication, and distribution channel. The dosage form segment includes gels, ointments, eye solutions & suspensions, eye drops, and capsules & tablets.

Eye drops represent one of the most prevalent and convenient methods for administering medications to the eye. They offer targeted therapy to the affected area, ensuring a swift onset of action. Ophthalmic eye drops, a category of liquid ophthalmic dosage forms, are specifically designed for direct instillation into the eye to address various eye conditions.

Comprising active pharmaceutical ingredients (APIs), ophthalmic eye drops feature these components dissolved or suspended in a sterile, aqueous liquid vehicle. Typically, the liquid vehicle takes the form of a water-based or saline solution, ensuring compatibility with delicate ocular tissues. Some eye drops may include preservatives to thwart microbial contamination in multi-dose formulations, though certain products are crafted as preservative-free to minimize the risk of irritation.

The formulation and manufacturing of eye drops adhere to stringent aseptic conditions to guarantee sterility, thereby reducing the likelihood of infection upon application to the eye. Careful adjustments are made to the pH and osmolarity of eye drops, aligning them with the ocular environment to minimize irritation and uphold eye comfort.

Ophthalmic gels represent a semi-solid form of ophthalmic medication utilized for addressing various eye conditions. Possessing a gelatinous texture, these gels are specifically formulated for topical application on the eye surface or eyelids. Engineered to ensure prolonged interaction with ocular tissues, they facilitate controlled drug release, promoting enhanced drug absorption, and consequently, longer-lasting therapeutic effects.

Comprising an amalgamation of active pharmaceutical ingredients (APIs) and a gel-forming agent, ophthalmic gels owe their gel structure and consistency to the latter. Commonly employed gel-forming agents in these gels encompass carbomers, cellulose derivatives like hydroxypropyl methylcellulose (HPMC), and polyvinyl alcohol.

Some of the prominent companies in the North America ophthalmic drugs market include Pfizer Inc, AbbVie Inc, Bausch Health Companies Inc, etc

Pfizer Inc develops, manufactures, and commercializes biopharmaceuticals. The company provides a range of products for addressing diverse conditions, including cardiovascular, metabolic, and pain-related issues, as well as women’s health, cancer, inflammation, immune disorders, and rare diseases. Additionally, it offers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and services for contract manufacturing. The company has major manufacturing facilities in the US, Singapore, Germany, Belgium, Italy, Ireland, Japan, China, and India, with headquarters in New York, the United States. 

One of its key products, XALATAN, is a prescribed medication designed to manage eye pressure, with potential benefits in lowering the likelihood of visual field deterioration and open-angle glaucoma.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Therapeutic Class, Dosage Form, Type, Indication, Distribution Channel
Countries AnalyzedThe United States and Canada
Companies AnalyzedAbbVie Inc, Accutome Inc, Bausch Health Companies Inc, Genentech Inc, Johnson & Johnson, Thea Pharma Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
    5. MAJOR MARKET FINDINGS
      1. EMERGING THERAPIES FOR DRY EYE SYNDROME
      2. GROWING DEMAND FOR COMBINATION THERAPIES
      3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
      4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. AGING POPULATION’S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
      2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
      3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
      4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
    2. KEY RESTRAINTS
      1. DELAY IN DRUG APPROVALS
      2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. TECHNOLOGY SNAPSHOT
      1. BIOLOGICS
      2. CELL THERAPY
      3. GENE THERAPY
      4. DRUG DELIVERY
      5. SMALL MOLECULE
      6. OTHER TECHNOLOGIES
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
    5. MARKET MATURITY ANALYSIS
    6. MARKET CONCENTRATION ANALYSIS
    7. KEY BUYING CRITERIA
    8. REGULATORY FRAMEWORK
  5. MARKET BY INDICATION
    1. DRY EYE
    2. GLAUCOMA
    3. INFECTION/INFLAMMATION/ALLERGIES
    4. RETINAL DISORDER
      1. WET AGE-RELATED MACULAR DEGENERATION
      2. DRY AGE-RELATED MACULAR DEGENERATION
      3. DIABETIC RETINOPATHY
      4. OTHER RETINAL DISORDERS
    5. OTHER INDICATIONS
  6. MARKET BY TYPE
    1. PRESCRIPTION DRUGS
    2. OVER-THE-COUNTER DRUGS
  7. MARKET BY DOSAGE FORM
    1. GELS
    2. EYE SOLUTIONS & SUSPENSIONS
    3. CAPSULES & TABLETS
    4. EYE DROPS
    5. OINTMENTS
  8. MARKET BY THERAPEUTIC CLASS
    1. ANTI-GLAUCOMA
    2. ANTI-INFECTION
    3. ANTI-INFLAMMATORY
    4. ANTI-ALLERGY
    5. OTHER THERAPEUTIC CLASSES
  9. MARKET BY DISTRIBUTION CHANNEL
    1. HOSPITAL PHARMACIES
    2. DRUG STORES
    3. ONLINE PHARMACIES
    4. OTHER DISTRIBUTION CHANNELS
  10. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA OPHTHALMIC DRUGS MARKET DRIVERS
      3. NORTH AMERICA OPHTHALMIC DRUGS MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ABBVIE INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      2. ACCUTOME INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      3. BAUSCH HEALTH COMPANIES INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      4. GENENTECH INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      5. JOHNSON & JOHNSON
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      6. THEA PHARMA INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      7. NOVARTIS AG
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      8. PFIZER INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      9. REGENERON PHARMACEUTICALS INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      10. SANTEN PHARMACEUTICAL CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      11. SUN PHARMACEUTICAL INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      12. TEVA PHARMACEUTICALS INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – OPHTHALMIC DRUGS

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 5: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 7: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 9: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 10: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 11: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 12: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 17: KEY PLAYERS OPERATING IN NORTH AMERICA OPHTHALMIC DRUGS MARKET

TABLE 18: LIST OF MERGERS & ACQUISITIONS

TABLE 19: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 20: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING

FIGURE 4: MARKET MATURITY ANALYSIS

FIGURE 5: MARKET CONCENTRATION ANALYSIS

FIGURE 6: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2022

FIGURE 7: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2032 (IN $ MILLION)

FIGURE 8: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2032 (IN $ MILLION)

FIGURE 9: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2032 (IN $ MILLION)

FIGURE 10: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2032 (IN $ MILLION)

FIGURE 11: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY RETINAL DISORDER, IN 2022

FIGURE 12: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)

FIGURE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)

FIGURE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2032 (IN $ MILLION)

FIGURE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2032 (IN $ MILLION)

FIGURE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER INDICATIONS, 2023-2032 (IN $ MILLION)

FIGURE 17: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 18: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 19: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 20: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DOSAGE FORM, IN 2022

FIGURE 21: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2032 (IN $ MILLION)

FIGURE 22: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2032 (IN $ MILLION)

FIGURE 23: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2032 (IN $ MILLION)

FIGURE 24: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2032 (IN $ MILLION)

FIGURE 25: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2032 (IN $ MILLION)

FIGURE 26: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY THERAPEUTIC CLASS, IN 2022

FIGURE 27: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2032 (IN $ MILLION)

FIGURE 28: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2032 (IN $ MILLION)

FIGURE 29: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2032 (IN $ MILLION)

FIGURE 30: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2032 (IN $ MILLION)

FIGURE 31: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC CLASSES, 2023-2032 (IN $ MILLION)

FIGURE 32: NORTH AMERICA OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022

FIGURE 33: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 34: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2032 (IN $ MILLION)

FIGURE 35: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 36: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER DISTRIBUTION CHANNELS, 2023-2032 (IN $ MILLION)

FIGURE 37: NORTH AMERICA OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 38: UNITED STATES OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: CANADA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FAQ’s